The weekly litigation news digest is live. Subscribe now

IP Verse

Methods For Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And Oxaliplatin - EP3337478

The patent EP3337478 was granted to Ipsen Biopharm on Aug 12, 2020. The application was filed on Aug 19, 2016 under application number EP16758337A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3337478

IPSEN BIOPHARM
Application Number
EP16758337A
Filing Date
Aug 19, 2016
Status
Granted And Under Opposition
Jul 10, 2020
Publication Date
Aug 12, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
GENERICS UKMay 12, 2021ELKINGTON AND FIFEADMISSIBLE
SANDOZMay 6, 2021KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (1) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS8147867

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents